Published in Health and Medicine Week, August 15th, 2005
Stereotaxis and the UVAPF entered into an agreement that eliminates any requirement for the company to pay royalties on Stereotaxis products that address clinical applications in the cardiovascular, peripheral vascular and certain other clinical fields. In exchange Stereotaxis has agreed to pay UVAPF a 1-time cash settlement payment of $3.65 million.
This resolution, which was amicably reached, absolves Stereotaxis of any obligations for future royalty payments in its primary areas of clinical focus....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week